Glioblastoma is a leading cause of cancer-related death in pediatric patients.
There are no approved therapies for Pediatric Brain tumors.
Current therapies are ineffective and have devastating side effects.
Treovir’s G207 Therapy demonstrated improved survival in a Phase 1 study without any serious side effects.
University of Alabama at Birmingham and Children’s of Alabama
Nick Tasoglou came to UAB and Children’s of Alabama after being diagnosed with a brain tumor. 5 months after G207 treatment, scans showed holes forming in the tumor at the G207 injection sites. More than 4 years after a single G207 treatment, with no other therapies, Nick has shown a strong response.
Check Out What's New
Treovir Announces Positive Results of Phase 1 Study of G207 in Pediatric Patients with Recurrent High-Grade Gliomatechknow
New England Journal of Medicine published the Phase 1 trial data on April 10,...
Treovir announces that it has been awarded a $2 million Phase 2 SBIR grant...